A Phase 1 interventional study of RAD001 and SOM230 in Neuroendocrine Tumors, sponsored by Novartis Pharmaceuticals. Completed at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing everolimus in Neuroendocrine Tumors — 1 open to participants now, 2 under way, none of them phase 3. Everolimus · Neuroendocrine Tumors.
Among the 22 studies testing everolimus in Neuroendocrine Tumors, this one is the 18th largest by enrollment, is one of 4 that started in 2012, is one of 6 in phase 1, and was the 11th registered.
543 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.
Browse Neuroendocrine Tumors studies →1 of the 22 studies testing everolimus in Neuroendocrine Tumors is open now, in 1 country. Recruiting first, the newest first:
AC Camargo Cancer Center · Sites in Brazil
Ages 16+
By country, each count listing its studies:
Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 11 · Phase 3 2 · Phase 4 3
First in 2006; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 41 across 387 interventional studies indexed under Neuroendocrine Tumors.
Median enrollment 38 across the 22 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
18 studies in Neuroendocrine Tumors by Novartis: none open now, 1 under way, none of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 18 studies in Neuroendocrine Tumors by Novartis, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2012, is one of 2 in phase 1, and was the 9th registered.
Novartis’s Neuroendocrine Tumors studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing everolimus in Neuroendocrine Tumors, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 18 in Neuroendocrine Tumors:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate long-term safety and tolerability of pasireotide LAR in combination with everolimus in advanced metastatic NET patients, who who have not progressed during 12 months of combination therapy with pasireotide LAR and everolimus
Inclusion and Exclusion Criteria:
Patients eligible for inclusion in this extension study have to meet all of the additional inclusion criteria:
No intolerable toxicity during combination therapy with pasireotide LAR and everolimus
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Number of Participants with Adverse Events and Serious Adverse Enents as a Measure of Safety and Tolerability
Time frame: up to 4 years
Number of Participants with abnormal laboratory and ECG results as a Measure of Safety and Tolerability
Time frame: up to 4 years
investigator-assessed progression free survival (PFS)
Time frame: up to 4 years
best overall response
Time frame: up to 4 years
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from May 2012 to primary completion in Sep 2018, 75 months.
Of 54 phase 1 interventional studies under Neuroendocrine Tumors, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 75. This study's 75 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus